Clinical Trial Update: Efficacy of Ra-223 in PSMA PET Optimally Selected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy of Radium-223 dichloride in PSMA PET–selected patients with castration-resistant, metastatic prostate cancer involv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: University of California, San Francisco | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Status: ACTIVE_NOT_RECRUITING